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Introduction: Blood culture (BC) testing before initiation of antimicrobial therapy is recommended as a standard
of care in international sepsis guidelines and has been shown to reduce intensive care unit (ICU) stay, antibiotic use,
and costs in hospitalized patients. Whereas microbiological laboratory practice has been highly standardized,
shortfalls in the preanalytic procedures in the ICU (that is indication, time-to-incubation, blood volume and numbers
of BC sets) have a significant effect on the diagnostic yield. The objective of this study was to gain insights into
current practices regarding BC testing in intensive care units.
Methods: Qualitative survey, data collection by 138 semi-structured telephone interviews in four European
countries (Italy, UK, France and Germany) between September and November 2009 in 79 clinical microbiology
laboratories (LABs) and 59 ICUs.
Results: Whereas BC testing is expected to remain the gold standard for sepsis diagnostics in all countries, there
are substantial differences regarding preanalytic procedures. The decision to launch BC testing is carried out by
physicians vs. ICU nurses in the UK in 92 vs. 8%, in France in 75 vs. 25%, in Italy in 88 vs. 12% and in Germany in
92 vs. 8%. Physicians vs. nurses collect BCs in the UK in 77 vs. 23%, in France in 0 vs. 100%, in Italy in 6 vs. 94% and
in Germany in 54 vs. 46%. The mean time from blood collection to incubation in the UK is 2 h, in France 3 h, in
Italy 4 h, but 20 h in German remote LABs (2 h in in-house LABs), due to the large number of remote nonresident
microbiological laboratories in Germany. There were major differences between the perception of the quality of BC
testing between ICUs and LABs. Among German ICU respondents, 62% reported that they have no problems with
BC testing, 15% reported time constraints, 15% cost pressure, and only 8% too long time to incubation. However,
the corresponding LABs of these German ICUs reported too many false positive results due to preanalytical
contaminations (49%), insufficient numbers of incoming BC sets (47%), long transportation time (41%) or cost
pressure (18%).
Conclusions: There are considerable differences in the quality of BC testing across European countries. In Germany,
time to incubation is a considerable problem due to the increasing number of remote LABs. This is a major issue of
concern to physicians aiming to implement sepsis guidelines in the ICUs.* Correspondence: frank.brunkhorst@med.uni-jena.de
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Blood culture (BC) testing before initiation of antimicro-
bial therapy is recommended as a standard of care in
international sepsis guidelines [1] and has been shown to
contribute to a decrease in ICU stay [2-4]. Furthermore,
BC testing is one of the cornerstones for antibiotic
stewardship programs, which has been shown to reduce
antibiotic overuse and costs in hospitalized patients [5,6].
Beside limitations of BC testing, for example anti-
biotic/antimycotic treatment prior to sampling, low pro-
portion of causative agents in the blood samples, and
frequent fastidious or noncultivable organisms [7-9], a
high degree of standardization in microbiological labora-
tory (LAB) practice warrants for an overall positivity of
approximately 30 to 40% in case of severe sepsis or sep-
tic shock [10]. In a recent large multicenter trial from
Germany [11] 33% of patients with severe sepsis or
septic shock had proven bacteremia. This is in contrast
to a rate of only 9.6% of positive blood cultures observed
in clinical practice in German ICUs aside from proto-
colized care [12] and underlines shortfalls in the pre-
analytic procedures in the ICU. Such shortfalls cover
inadequate skin antisepsis and sampling techniques, as
access via intravenous catheters, low blood volumes and
low numbers of BC sets drawn for inoculation, pro-
longed time to incubation, suboptimal preincubation
prior to automated cultivation at 37°C, which have a
significant effect on the diagnostic yield [13-15].
The numbers of BC sets processed per hospitalized
patients are off particular importance. According to the
case mix of the hospital, inoculation of 100 to 200 BC
sets per 1,000 patient days is recommended [16,17].
These numbers are, however, far from routine use, at
least in Germany, where 55 BCs per 1,000 patient days
were surveyed in 201 ICUs in 2009 in contrast to
France, where 165 BCs per 1,000 patient days were
quoted [18]. The 2010 annual report of the European
Antimicrobial Resistance Surveillance Network (EARS-
Net) specified only 12.1 BCs per 1,000 patient days in 37
hospitals in Germany, compared to 46.5 in 27 hospitals
in France, 46.1 in 26 hospitals in the UK, and 70.7 BCs
per 1,000 patient days in 22 hospitals in Italy [19]. In a
recent study published by the National Reference Centre
for Hospital Infections (NRZ), data of the German
hospital nosocomial infection surveillance system (KISS)
from 2006 were used to investigate the association be-
tween the frequency of blood cultures and central venous
catheter-associated bloodstream infection (CVC-BSI) rates
in 223 intensive care units (ICU) [20]. The median
number of BC sets taken was 60 with a huge variation
from 3.2 to 680 per 1,000 patient days. The authors
concluded that if an external benchmarking of CVC-
BSI rates is intended, an adjustment according to the
BC frequency is necessary.Reasons for the disregard of current guidelines have
been identified, among others, in infrastructural aspects.
The number of infections confirmed by LABs closely
depends on the availability of closely located LABs [12],
which sets a focus for future improvements of uniform
customs and recommendations and of technical proce-
dures on the preanalytic side of BC routine. Fur-
thermore, there may be differences in the quality of BC
testing between countries since the establishment of
clinical microbiology and infectious disease departments
vary substantially among European countries. Especially
in Germany, patient-centered clinical microbiology is
only a branch of laboratory medicine [21].
The aim of this qualitative survey was to assess the
current practice in BC testing in ICUs and LABs across
four European countries. Issues were technical aspects
of the preanalytic course and an assessment of the
current practice and their quality on the basis of individ-
ual perceptions among the staff and directors of ICUs
versus LABs.
Materials and methods
Some 138 interviews were conducted between September
and November 2009 in 79 microbiological laboratories
(LABs) and 59 intensive care units (ICUs) in France,
Germany, Italy, and UK (Table 1). Pediatric and neonatal
ICUs were excluded. Interviewees were ICU directors,
ICU residents, ICU nurses, LAB directors, and LAB man-
agers. The survey was carried out by an international
agency (Advention BP, London, UK) on behalf of BD
Diagnostics (Heidelberg, Germany). To uncover prevalent
trends in thought and opinion, the interview panel was se-
lected to fulfill a given quota, for example per country 10
to 20 ICUs and microbiological laboratories, respectively.
Furthermore, the panel had to be balanced between BD
Diagnostics (49.5%) and bioMérieux (Craponne, France)
(50.5%) customers. Data were collected using semi-
structured techniques for example individual in-depth
personal telephone interviews. The interview guide in-
cluded, among others, a list of general topics and open
questions such as sepsis awareness and indication for BC
testing, preanalytic procedures, sample transport and pre-
incubation, and BC processing and communication of re-
sults (see Table S1 in Additional file 1). The response rate
was 100 percent, since personal interviews have the poten-
tial to overcome the poor response rates of a question-
naire survey [22]. According to the requirements of the
ethics committee of Jena University Hospital (Jena,
Germany), the survey needed no ethical approval.
Results
Sepsis awareness
Throughout all countries surveyed, sepsis and its timely
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Figure 1 BCs processed by 79 LABs from 59 ICUs in four
European countries. Given are mean numbers of BC sets processed
in the LABs per patient within 24 hours and the average number of
BC sets taken per patient in the ICUs (below). BC, blood culture; LAB,
microbiological laboratory.
Table 1 Interviewees participating in the survey
Interviewees (n) France Germany Italy UK Total
Total (n) 39 32 30 37 138
ICUs (n) 16 13 17 13 59
LABs (n) 23 19 13 24 79
Type of structure (%)
Private 10 37 0 0 12
Public 90 63 100 100 88
ICUs
Private 0 23 0 0 5
Public 100 77 100 100 95
LABs
Private 17 47 0 0 16
Public 83 53 100 100 84
Interviewee position (n)
ICUs
Head of ICU 3 6 0 0 9
Physician 7 7 12 12 38
Nurse 6 0 5 1 12
LABs
LAB director 8 17 5 5 35
LAB manager 5 0 3 15 23
Microbiologist 10 2 5 4 21
LAB, microbiological laboratory.
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important for 46% of interviewees in the UK, 43% in
Italy, and 30% in Germany, due to its high incidence and
mortality, and the importance of timely diagnosis for
recovery. Medical staff in all countries noted increasing
efforts how to detect and treat sepsis and how to imple-
ment educational programs for infection control in their
hospitals. In the UK, critical care outreach teams have
been established in certain hospitals in order to increase
the medical staff ’s awareness throughout the hospital [23].
Indication for BC testing
All interviewees claimed that in their institutions BCs
are collected and broad-spectrum antibiotics are admin-
istered immediately, if sepsis is suspected clinically. In
general, the four systemic inflammatory response syn-
drome (SIRS) criteria of body temperature (fever (≥38°C)
or hypothermia (≤36°C)), heart rate (tachycardia ≥90
heartbeats per minute), respiratory rate (tachypnea ≥20
breaths/minute or hyperventilation pCO2 <36 mmHg),
and white blood cell count (leucocytosis (>12,000 cells/μl),
leucocytopenia (<4,000 cells/μl), presence of immature
neutrophiles) are monitored. The presence of one suspi-
cious sign (especially the presence of fever) is usually suffi-
cient to launch a BC. If more than one sign is present, asystematic workup is initiated. Further standard cultures
(for example, urine, tracheal specimen, wound, cerebral
fluids, and other swabs) are regularly performed.
Preanalytic procedures
Numbers of BCs cultured
Most ICUs claimed to collect between two and three BC
sets per patient with varying numbers by country
(Figure 1). In contrast, wards collect only between 1.3
(Germany) and 1.8 (France) BC sets per patient. Less
than 15% of ICUs claimed to collect less than two BC
sets per patient. ICUs account for a significant propor-
tion of BC sets processed in LABs, ranging from 15% in
the UK to 33% in Germany.
Launch of BCs
Considerable country-specific differences were identified
regarding BC collection and processing, including trans-
portation to the LAB, timely feedback and communica-
tion procedures of results back to the ICU. While the
decision to order a BC is typically taken by physicians in
all countries, blood sampling is mainly carried out by
physicians in the UK, by nurses in France and Italy, and
by both in Germany (Table 2).
Sampling technique
Techniques for blood sampling vary across countries
(Table 2). A fresh peripheral venipuncture is more pre-
ferred in Germany and Italy, while blood collection via an
intravenous catheter is more preferred in France and the
UK. For collection, traditional systems (that is syringe
Table 2 Collection, transport and processing of BCs in
four European countries
France Germany Italy UK
Sample transport
Time to incubation (h)
On-site LABs 3 2 4 2
Remote LABs - 20 - -
Cultures incubated with a
delay of >8 h (%)
On-site LABs 9 10 9 6
Remote LABs - >60 - -
Modes of transportation (%)
Van 36 71 23 15
Porter 32 0 77 50
Pneumatic tube 32 29 0 35
LAB opening hours (%)
8 h 5 days per week 41 40 31 19
8 h 7 days per week 41 40 46 62
24 h 7 days per week 18 20 23 19
BC management outside
LAB opening hours (%)
Storage at room temperature 73 86 67 27
(up to 12 h delay)
Access to BC system in the LAB 27 0 33 73
(1 h delay)
Access to BC system in the
ICU (no delay)
0 14 0 0
Interest in relocation of BC
systems into ICU (%)
LABs 22 47 33 21
ICUs 17 88 86 0
Decision to launch BC (%)
Physician 75 92 88 92
Nurse 25 8 12 8
Responsible for BC collection (%)
Physician 0 54 6 77
Nurse 100 46 94 23
Mode of BC collection (%)
Intravenous catheter only 33 8 0 23
Peripheral venipuncture only 20 42 76 23
Both 47 50 24 54
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Figure 2 Blood volumes collected per BC bottle in 59 ICUs in
four European countries. Given are mean blood volumes filled
into BC bottles and processed in the LABs. The mean volumes per
bottle are given below. BC, blood culture; LAB,
microbiological laboratory.
Schmitz et al. Critical Care 2013, 17:R248 Page 4 of 9
http://ccforum.com/content/17/5/R248and needle) or closed systems (that is winged collec-
tion sets, vacuum systems) are used in all countries.
Closed systems are primarily used in France (71%),
whereas Germany has the highest rate in the usage of
syringes and needles (42%).Blood volumes collected
Blood volumes collected per bottle vary between an
average of 8.3 ml in France to 11.5 ml in Italy, while
the majority of ICUs collect 8 to 12 ml of blood per
bottle as requested by the LABs. Some 86% of the
ICUs are aware that pathogen detectability is directly
proportional to the amount of blood volume per bottle
taken (Figure 2).
Sample transport and preincubation
Time to incubation depends on transportation time,
LAB opening hours, and BC management outside these
timelines. Time-to-incubation ranges from 2 h in the
UK and up to 20 h in German remote nonresident LABs
(Table 2). For transportation, mainly vehicles/vans are
used in Germany, where 23% of LABs are private, non-
resident LABs. In Italy and in the UK transport service
personnel is predominantly responsible for BC trans-
portation within the hospital. In-house pneumatic tube
systems are used in an about one-third of hospitals in
France, Germany and the UK, but are not available or
not used in Italy for BC transportation (Table 2).
The majority of LABs are closed overnight in all coun-
tries. Only about 40% offer services on weekends, with
the exception of UK, where 62% are opened during
weekends. Many LABs have on-call services for infec-
tious emergencies. However, this service is rarely avail-
able for BC testing and management. Accordingly, the
majority of BCs are stored at room temperature outside
LAB opening hours, except in the UK where cultures
are often preincubated in the LAB, which is served
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number of private nonresident LABs in Germany,
14% of German ICUs have established a local BC in-
cubator device in order to shorten time to incubation.
Remarkably, 88% of German and 86% of Italian ICUs
are interested in the relocation of the BC incubation
device at their ICUs. This is also supported by 47% of
German and 33% of Italian LABs. The interest is conside-
rably lower in the UK (ICUs: 0%, LABs: 21%) and in
France (17%/22%) (Table 3).
BC processing, report of results and communication
strategies
On average, LABs process 50 BC sets per day, ranging
from 35 in the UK to 58 in Germany with a positivity
rate of 12 to 13%. However, identification and antibiotic
susceptibility testing (ID/AST) is not performed on all
positive cultures (9% in France, 13% in Germany and
Italy and 12% in the UK) (Figure 3).
Positive culture results are usually communicated over
the phone across all countries, while ID/AST results are
communicated to the physicians only in the UK, France,
and Italy. Negative results are poorly communicated
immediately, but are sent out as a written report at theTable 3 Major challenges regarding BC testing in sepsis
routine identified in 79 ICUs and 59 LABs across four
European countries
Challenges (%) France Germany Italy UK
ICUs
No challenges 50 62 18 38
Time constraints 19 15 41 8
Cost pressure 0 15 41 15
Insufficient training of personnel 0 0 18 31
Excessive time to transport 0 8 12 0
Poor communication with LAB 13 0 6 0
Other 25 0 6 8
LABs
No challenges 19 31 18 46
Excessive time to transport 4 37 23 0
Insufficient incoming sample
volumes/number of BC sets
43 42 0 21
Cost pressure 9 16 54 29
Mislabeling of BC bottles 13 0 23 4
Many false negatives 9 21 8 17
Many false positives due to
Inappropriate taking of blood samples 61 53 0 38
Delayed transport to the LAB 9 0 8 0
Low reactivity of clinicians 0 11 0 4
BC, blood culture; LAB, microbiological laboratory.end of the analysis. The quality of interaction between the
LAB and the ICU is perceived as very good in all countries
except in Germany, where microbiologists complain about
the poor reactivity of clinicians, when positive BCs require
discussion and some German ICU physicians complain
about the poor quality of communication with LABs,
leading to delayed or incomplete transmission of results
(Table 3).
In general, perceptions vary substantially between ICU
physicians and LABs (Table 3). Some 42% of ICU physi-
cians do not see any challenges in BC testing, compared
to 29% of LAB physicians, who address several severe
limitations in BC testing, especially in Germany.
LABs acknowledge the insufficient incoming number
of BC sets and blood volumes (27%), the high rate of
false positives due to non-proper skin antiseptics and
collection via intravenous catheters (38%), and the cost
pressure, limiting the type and number of BC sets (27%).
Cost pressure is a major challenge in Italy, where 41% of
ICUs and 54% of LABs agree upon this limitation.
Excessive time to transport from the ICU to the LAB
is a major challenge especially in Germany and Italy
(37% and 23%). Germany and France have the highest
rates in insufficient numbers of BC sets and low blood
volumes taken (42% and 43%) and the highest rates of
false positive BCs due to inappropriate taking of blood
samples (53% and 61%).
Notably, in the UK, LABs have a strong role in the
decision to initiate antibiotic treatment, while in France
and Germany ICU physicians are more responsible in
their choice of antibiotics.
Discussion
Blood culture testing is definitively the gold standard
and primary test to evaluate patients with sepsis [24].
However, despite European efforts to standardize BC
testing similar to the US Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines [17], there are different
perceptions regarding the performance of BC testing
between the interviewees from four European countries
in our survey.
The S2k guidelines of the German Sepsis Society (GSS)
[25] (see Table S2 in Additional file 2), the Italian Progetto
LaSER [26], and the Britain Saving Lives (NHS) guidelines
[27] recommend ≥2 BC sets in case of sepsis suspicion,
which is supported by the recent international guidelines
of the Surviving Sepsis Campaign (SSC) [1], whereas the
French National Society of Anaesthesia and Intensive Care
(SFAR) give no recommendations.
Major challenges in BC testing are low rates of true
positivity due to antibiotic pretreatment prior to blood
withdrawal, suboptimal sample volume, an inadequate
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% of 
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Figure 3 Number of BC sets processed and ID/AST tests performed per day (mean) in microbiological LABs in four European countries.
The mean percentage of positive BC sets processed per day and LABs are given below. BC, blood culture; ID/AST, identification and antibiotic
susceptibility testing; LAB, microbiological laboratory.
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found that only 45% of patients had adequate numbers
of BC sets and only 13% had optimal sample volumes
(that is ≥10 ml per bottle) [28]. The authors of a review
on true-positive rate, contamination rate, and collected
blood volume of BC bottles in five Belgian hospital
laboratories found that more than one-third of the BC
bottles handled were incorrectly filled, irrespective of the
manufacturer of the blood culture vials [29].
In our survey, blood volumes collected per BC bottle
varied considerably between countries with on average
less than 10 ml per bottle (8.3 ml in France, Italy with
11.5 ml as an exception), though ICU staff is aware of
the fact that BC positivity is proportional to the blood
volume taken.
Differences in qualities of recommended blood sam-
pling for BCs (number of sets and volume per bottle)
may be partly explained by different responsibilities
among the ICU staff. BC sampling is mainly carried out
by physicians in the UK, by nurses in France and Italy,
and by both in Germany.
In our survey, time to incubation of BCs ranged from
2 h in the UK and up to 20 h in German remote LABs.
Limitations in transport times for BCs had been repor-
ted by Kerremans et al. in the Netherlands [30]. The
median transport time in this study was 3.5 h, with 47%
of cultures exceeding the recommended 4 h. Off-site
location and type of clinical specialty were the most
important predictors of long transport times. Culturescollected during weekend days or on wards at the largest
distances from the laboratory were also associated with
long transport times.
Considerable differences between countries were ob-
served with regard to blood transport and storage prior
to automated incubation in our survey. Delays in trans-
port times were mainly due to different transport modes
(that is, via van, porter, or pneumatic tube) and infra-
structure. With Germany as an obvious exception, LABs
are usually closely related to hospitals resulting in a
transport time ≤4 h. Together with a general trend to
store blood during closing times at room temperature,
which accounts for a further delay of ≤12 h, up to 20 h
time to incubation occurs in Germany. In consequence,
up to 14% of German ICUs already have direct access to
an on-site BC incubation device. The impact of immediate
incubation of BCs delivered to the laboratory outside its
hours of operation on turnaround times, antibiotic pre-
scription practices, and patient outcomes was assessed by
Kerremans et al. in a study from the Netherlands [31].
The authors found no difference in length of stay or
hospital mortality, but immediate incubation of BCs out-
side laboratory hours reduced turnaround times and
accelerated antibiotic switching.
Positive BC results are of paramount importance for
patient management. Similarly to surgery, where the close
cooperation with the pathologists of hospitals guarantees
the intraoperative rapid section with immediate diagnosis
within a few hours, BC results have to be considered as
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ical professional (physician, nurse practitioner) respon-
sible for the coordination of BC testing between LABs
and ICUs.
Furthermore, since many patients are seen at an emer-
gency department at first instance and initial BCs are
taken there, it is the responsibility of the LABs to deter-
mine the location of the patient once the cultures are
positive. Our survey shows that most LABs transmit
preliminary results (that is, on Gram-staining behavior
of the microorganisms grown in culture) via telephone,
allowing clinical professionals to fine-tune the initial
empiric antibiotic treatment. Final results, including ID/
AST information, are mostly sent via facsimile or as a
written letter report. This is due to the complex nature
of the information (resistance-testing results for >10
antibiotics) and to time and cost reasons. Direct oral or
face-to-face communication is established in all inter-
viewees’ countries except Germany. However, improving
communication of BC results (including negative results)
have been shown to reduce antibiotic usage in neonatal
intensive care units [32]. Telephone transmission of
critical laboratory results may be inaccurate. However, a
study by Howe et al. showed only minor transmission
errors [33].
Our study has several limitations. First, aberrations
from guidelines may notably in part be due to the gen-
eral phenomenon that treatment recommendations in
ICUs only poorly comply with practice recommenda-
tions: ICU directors perceive adherence to be higher
than it actually is [34]. We did not perform an audit on
order to assess actual practice. However, the results of
this survey show that even perception of current BC
practices in European ICUs is suboptimal. Second, the
survey was qualitative in nature, so only semi-structured
techniques with open questions were applied and res-
pondents were not randomly selected and our findings
are not representative. For instance, the proportion of
BC sets processed in LABs is influenced by the case mix
of ICUs. In addition, we have no quantitative data on
preanalytic procedures, that is, contamination data,
blood volume, and routine practice subsequent to inocu-
lation of BC bottles. Furthermore, due to the exploratory
outcome of our research, a statistical analysis was not
performed and our data cannot be used to make
generalizations. However, by providing insights into
BC testing practices in European ICUs, our study
generates ideas and hypotheses for later quantitative
research. Finally, we did not assess knowledge and
attitudes concerning interpretation of BC results and,
more importantly, therapeutic consequences. However,
guideline-based collection, processing and reporting of
BCs are the cornerstones for successful patient man-
agement [35].Conclusions
Evidence-based blood culture testing is of utmost im-
portance for ICU patients with suspected sepsis. Know-
ledge of the etiologic agent (bacteria or fungi) and their
susceptibility against antimicrobials enables the clinician
to initiate an appropriate antimicrobial therapy and to
guide diagnostic procedures. Whereas microbiological
laboratory practice has been highly standardized, short-
falls in the preanalytic procedures in the ICU (indication,
timing, volume, numbers, collection of blood cultures)
have a significant effect on the diagnostic yield. Imple-
mentation strategies involving all ICU staff are needed
to overcome the gap between recommended best prac-
tices and national guidelines. Finally, the BC frequency
per 1,000 patient days should be established as a quality
indicator in ICUs.
Key messages
 There are considerable differences in the quality of
BC testing across European countries and also in the
perception of the quality of BC testing between
ICUs and LABs.
 Positive BC results are of paramount importance for
patient management. Rapid communication of BC
results has to be considered as an emergency.
Implementation strategies involving all ICU staff are
needed to improve BC testing.
 If an external benchmarking of CVC-BSI rates is
intended, an adjustment according to the BC fre-
quency is necessary.
Additional files
Additional file 1: Table S1. Issues addressed in the interview guide.
Additional file 2: Table S2. Guideline-based blood culture testing
(according to [10]).
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